Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?

Lipoprotein oxidation is believed to play an important role in atherogenesis. To investigate whether inhibition of oxidation of low density lipoprotein (LDL) would alter atherogenesis in the nonhuman primate, we administered probucol, a potent antioxidant, to Macaca nemestrina fed a high-fat, high-cholesterol diet. Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos. To evaluate the antioxidant effect of probucol, the resistance of isolated plasma LDL to in vitro oxidation was evaluated. Probucol significantly increased the resistance of LDL to oxidative modification, as shown by an increase in the lag time required for conjugated diene formation. Lesions in the probucol-treated animals appeared less mature, and increased accumulation of lipid was observed in smooth muscle cells. Comparison of all control and probucol-treated monkeys demonstrated that intimal lesion areas in the thoracic aortas of the probucol-treated monkeys were reduced by 43% (P < 0.0001), but no significant difference in lesion area was found in the abdominal aortas or in the iliac arteries. However, the lag phase of conjugated diene formation was not prolonged in 2 of the 8 probucol-treated animals. A plot of intimal lesion size versus lag phase of all 16 animals showed a trend that lesion size was inversely related to oxidation resistance for all anatomic sites. The strong inverse relationship between intimal lesion size and resistance of LDL to oxidation supports a role for lipoprotein oxidation in the development and progression of lesions of atherosclerosis. The possibility that some of the effect is due to other biological properties of probucol cannot be ruled out.

[1]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[2]  R. Krauss,et al.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. , 1993, The American journal of medicine.

[3]  E. Stein,et al.  Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[4]  Margaret S. Wu,et al.  Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. , 1992, The Journal of clinical investigation.

[5]  S. Parthasarathy.  Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative. , 1992, The Journal of clinical investigation.

[6]  P. Reaven,et al.  Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  Y. Matsuzawa,et al.  Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques. , 1992, Atherosclerosis.

[8]  S. Yamashita,et al.  Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases. , 1992, Atherosclerosis.

[9]  A. Verlangieri,et al.  Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. , 1992, Journal of the American College of Nutrition.

[10]  A. Arntzenius,et al.  Progression and regression of atherosclerosis, what roles for LDL-cholesterol and HDL-cholesterol: a perspective. , 1991, European heart journal.

[11]  A. Gown,et al.  Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  P. Henriksson,et al.  The antioxidant butylated hydroxytoluene protects against atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[13]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[14]  G. Walldius,et al.  Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro. , 1990, Atherosclerosis.

[15]  R. Ross,et al.  Atherogenesis during low level hypercholesterolemia in the nonhuman primate. I. Fatty streak formation. , 1990, Arteriosclerosis.

[16]  R. Ross,et al.  Atherogenesis during low level hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. , 1990, Arteriosclerosis.

[17]  A. Tall,et al.  Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. , 1990, The Journal of clinical investigation.

[18]  M. Freeman,et al.  Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. , 1990, Nature.

[19]  T. Carew,et al.  Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. , 1989, Arteriosclerosis.

[20]  A Daugherty,et al.  Probucol attenuates the development of aortic atherosclerosis in cholesterol‐fed rabbits , 1989, British journal of pharmacology.

[21]  R. N. Brogden,et al.  Probucol , 1989, Drugs.

[22]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[23]  O. Stein,et al.  Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels. , 1989, Atherosclerosis.

[24]  H. Esterbauer,et al.  Continuous monitoring of in vitro oxidation of human low density lipoprotein. , 1989, Free radical research communications.

[25]  R. Jackson,et al.  Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. , 1988, The American journal of cardiology.

[26]  G. Franceschini,et al.  Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol. , 1988, The American journal of cardiology.

[27]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Chait,et al.  The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. , 1987, The Journal of biological chemistry.

[29]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Morel,et al.  Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[31]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[32]  S. Young,et al.  Probucol inhibits oxidative modification of low density lipoprotein. , 1986, The Journal of clinical investigation.

[33]  G. Warnick.  Enzymatic methods for quantification of lipoprotein lipids. , 1986, Methods in enzymology.

[34]  R. Pittman,et al.  Methods for assessment of tissue sites of lipoprotein degradation. , 1986, Methods in enzymology.

[35]  R. Ross,et al.  Studies of Hypercholesterolemia in the Nonhuman Primate: II. Fatty Streak Conversion to Fibrous Plaque , 1984, Arteriosclerosis.

[36]  A. Attie,et al.  A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. , 1983, The Biochemical journal.

[37]  G. Schonfeld,et al.  Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover. , 1983, Atherosclerosis.

[38]  M. Brown,et al.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.

[39]  D. Steinberg,et al.  Enhanced Macrophage Degradation of Biologically Modified Low Density Lipoprotein , 1983, Arteriosclerosis.

[40]  R. Wissler,et al.  Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas. , 1983, Applied pathology.

[41]  J. Segrest,et al.  Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. , 1980, Journal of lipid research.

[42]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[43]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[44]  G. Busk,et al.  A Manual of Pathological Anatomy , 1856, The British and foreign medico-chirurgical review.